ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective effect of tectorigenin against streptozotocin-induced gestational diabetes mellitus in rats via alteration of inflammation, oxidative stress, HO-1/Nrf2 and NF-κB/COX-2/iNOS signaling pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM) is a prevalent metabolic disorder during pregnancy, characterized by hyperglycemia and associated with significant maternal and fetal complications. The current study was investigating the protective effect of tectorigenin against streptozotocin (STZ)-induced GDM in rats. STZ was used for the induction of diabetes in the rats and pregnant rats that received the oral administration of tectorigenin and blood glucose level were estimated at different time intervals (day 3, day 12, and day 18). The foetus weight, placental weight and placental index, plasma insulin level, HOMA-IR, HOMA-β, HOMA-ISI, food intake, water intake, urine output, fecal output, hepatic glycogen, free fatty acid, serum C-peptide, antioxidant, inflammatory cytokines and inflammatory parameters were estimated. The different mRNA expressions were also estimated. Tectorigenin treatment significantly suppressed the blood glucose level and improved the insulin level. Tectorigenin treatment significantly altered the body weight, foetus weight, placental weight, placental index, water intake, food intake, urine output, fecal output, fasting insulin level, HOMA-IR, HOMA-β, HOMA-ISI, hepatic glycogen, serum C-peptide, free fatty acid and visfatin. Tectorigenin treatment significantly (P < 0.001) altered the level of lipid parameters (VLDL, TC, TG, HDL, LDL); antioxidant parameters (GPx, SOD, TAC, LPO, CAT, GSH); inflammatory cytokines (TGF-β, TNF-α, IL-1β, IL-6, IL-10, MCP-1); inflammatory parameters (NF-κB, COX-2, iNOS); ICAM-1, VCAM-1, HO-1 and Nrf
Indexed as
Identifiers
41774117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.